BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $KRYS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07016750-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~IOLITE readout (P3) · Krystal Biotech\, Inc. $KRYS
DESCRIPTION:A Study Comparing KB803 and Matched Placebo in Patients With Dy
 strophic Epidermolysis Bullosa\n\nPrimary completion date: 2026-12 (estima
 ted) — month only\, shown on the 1st\nOriginally planned: 2026-03 (+9.0 
 months)\nPhase 3 · Rare · Dystrophic Epidermolysis Bullosa\, DEB - Dystr
 ophic Epidermolysis Bullosa\, Recessive Dystrophic Epidermolysis Bullosa\n
 Enrollment: 16 · Sites: 5\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT07016750\nhttps://clinicaltrials.
 gov/study/NCT07016750
URL:https://datacutoff.com/radar.html?nct=NCT07016750
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
